Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Tharimmune ( (THAR) ).
On July 23, 2025, Tharimmune, Inc. announced a registered direct public offering of $1.74 million in securities, including common stock and warrants, with the offering closing on July 25, 2025. The proceeds from this offering are intended for working capital and general corporate purposes, with President Street Global, LLC acting as the exclusive placement agent. This move is expected to support Tharimmune’s strategic positioning in the biotechnology sector, enhancing its financial resources for ongoing and future projects.
The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.
More about Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates in immunology, inflammation, and oncology. The company’s lead clinical asset, TH104, is being developed for respiratory and/or nervous system depression in military personnel and chemical incident responders. Tharimmune also explores treatments for chronic pruritus in primary biliary cholangitis and autoimmune diseases, utilizing its proprietary EpiClick™ Technology for targeting solid tumors.
Average Trading Volume: 64,746
Technical Sentiment Signal: Sell
Current Market Cap: $6.29M
For an in-depth examination of THAR stock, go to TipRanks’ Overview page.